Other Clinical Trial - Clinical Utility Assay as a Biomarker for

Updated 06/21/2024

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate how well an investigational blood test performs. The study will look at the sensitivity and specificity of a blood-based multitranscriptome assay (NETest).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Gastroenteropancreatic Neuroendocrine Tumor
Lung Neuroendocrine Neoplasm
Neuroendocrine Tumors

Clinical Trial Details

NCT number	NCT02948946
Study type	Observational
Source	H. Lee Moffitt Cancer Center and Research Institute
Contact
Status	Completed
Phase
Start date	January 9, 2017
Completion date	September 15, 2020

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT06155318` - 68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours
	Terminated	`NCT01994213` - A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor	Phase 2
	Active, not recruiting	`NCT03980925` - Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.	Phase 2
	Recruiting	`NCT02611024` - Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors	Phase 1/Phase 2
	Completed	`NCT04852679` - Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs	Phase 3
	Enrolling by invitation	`NCT05064150` - Neuroendocrine Tumors - Patient Reported Outcomes
	Active, not recruiting	`NCT04727723` - Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
	Recruiting	`NCT06256705` - Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort	N/A
	Active, not recruiting	`NCT05477576` - Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy	Phase 3
	Recruiting	`NCT04609592` - Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery	Phase 1
	Recruiting	`NCT05701241` - Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients	Phase 4
	Withdrawn	`NCT04915144` - 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs	Phase 2
	Recruiting	`NCT04986085` - Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
	Active, not recruiting	`NCT05262556` - NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas	Phase 1
	Completed	`NCT03017690` - Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)